NCT06769113View on ClinicalTrials.gov

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 26, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

June 5, 2027

Conditions
Esophageal Cancer
Interventions
DRUG

HLX43 DOSE 1

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

DRUG

HLX43 DOSE 2

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

DRUG

HLX43 DOSE 3

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital, Jinan

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY